English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  For lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) sensitive mutation and synchronous brain metastasis (syn‐BM), when and how to apply radiotherapy (RT) during first‐line tyrosine kinase inhibitor (TKI) treatment remains debatable.    Methods  From a real‐world multicenter database,  EGFR ‐mutant patients with syn‐BM diagnosed between 2010–2020 and treated with first‐line TKIs were enrolled and divided into upfront TKI + RT and upfront TKI groups. Median intracranial progression‐free survival (mIC‐PFS), median overall survival (mOS), and their risk factors were estimated.    Results  There were 60 and 186 patients in the upfront TKI + RT group and upfront TKI group, respectively. Their mIC‐PFS were 28.9 months (m) and 17.5 m ( p  = 0.023), and mOS were 42.7 m and 40.1 m ( p  = 0.51). Upfront brain RT improved mIC‐PFS in patients ≤60‐year‐old ( p  = 0.035), with symptomatic BM ( p  = 0.002), and treated with first‐generation TKIs ( p  = 0.012). There was no significant difference in mOS in any subgroup. Upfront brain stereotactic radiosurgery (SRS) showed a trend of better mIC‐PFS and mOS. mIC‐PFS was independently correlated with symptomatic BM (HR = 1.54,  p  = 0.030), EGFR L858R mutation (HR = 1.57,  p  = 0.019), and upfront brain RT (HR = 0.47,  p  = 0.001). mOS was independently correlated with being female (HR = 0.54,  p  = 0.007), ECOG 3–4 (HR = 10.47,  p  &lt; 0.001), BM number&gt;3 (HR = 2.19,  p  = 0.002), and third‐generation TKI (HR = 0.54,  p  = 0.044) or antiangiogenic drugs (HR = 0.11,  p  = 0.005) as first/second‐line therapy.    Conclusions  Upfront brain RT based on first‐line EGFR‐TKI might improve IC‐PFS but not OS in  EGFR ‐mutant lung adenocarcinoma patients, indicating potential survival benefit from brain SRS and early application of drugs with higher intracranial activity.

thoracic cancer

Value and significance of brain radiation therapy during first‐line  EGFR‐TKI  treatment in lung adenocarcinoma with   EGFR   sensitive mutation and synchronous brain metastasis: Appropriate timing and technique